MiR-451 inhibits NSCLC tumor cell growth and migration by targeting LKB1/AMPK [87] and ATF2 [88] and sensitizes NSCLC cells to cisplatin by regulating Mcl-1 [89]. Here, ATF2 is linked to neoplasm.